奥美卡替对射血分数降低的慢性心力衰竭患者运动能力的影响:METEORIC-HF随机临床试验
METEORIC-HF为3期双盲安慰剂对照随机试验,纳入左心室射血分数≤35%、纽约心脏协会II-III级症状、N末端B型利钠肽原≥200 pg/mL且基线峰值摄氧量≤预测值75%的慢性射血分数降低的心力衰竭患者276例,按2:1随机接受奥美卡替(n=185)或安慰剂(n=91),口服每日两次,按目标血浆浓度给予25 mg、37.5 mg或50 mg,疗程20周。主要终点峰值摄氧量从基线至第20周的变化在两组间无显著差异(均值-0.24 mL/kg/min vs 0.21 mL/kg/min;最小二乘均值差-0.45 mL/kg/min [95%CI,-1.02至0.13];P=0.13)。作者结论认为这些发现不支持使用奥美卡替治疗射血分数降低的心力衰竭以改善运动能力。
要点
- 慢性射血分数降低的心力衰竭患者口服奥美卡替20周,峰值摄氧量变化与安慰剂无显著差异(-0.24 mL/kg/min vs 0.21 mL/kg/min;最小二乘均值差-0.45 mL/kg/min [95%CI,-1.02至0.13];P=0.13)。
- 奥美卡替组与安慰剂组不良事件:头晕4.9% vs 5.5%,乏力4.9% vs 4.4%,心力衰竭事件4.9% vs 4.4%,死亡1.6% vs 1.1%,卒中0.5% vs 1.1%,心肌梗死0% vs 1.1%。
- 作者结论:这些发现不支持使用奥美卡替治疗射血分数降低的心力衰竭以改善运动能力。
- 研究纳入左心室射血分数≤35%、纽约心脏协会II-III级症状、N末端B型利钠肽原≥200 pg/mL且基线峰值摄氧量≤预测值75%的患者,中位年龄64岁,中位左心室射血分数28%。
- 给药方案:口服每日两次,按目标血浆浓度给予25 mg、37.5 mg或50 mg,疗程20周。
适用人群与场景
- 慢性射血分数降低的心力衰竭患者,左心室射血分数≤35%,纽约心脏协会II-III级症状,N末端B型利钠肽原≥200 pg/mL,基线峰值摄氧量≤预测值75%。
诊断标准与关键阈值
- 左心室射血分数≤35%;纽约心脏协会心功能II-III级;N末端B型利钠肽原≥200 pg/mL;基线峰值摄氧量≤预测值75%。
处置流程与药物剂量
- 奥美卡替口服每日两次,按目标血浆浓度给予25 mg、37.5 mg或50 mg,疗程20周。
研究设计与关键结果
- 3期双盲安慰剂对照随机试验,276例患者按2:1随机接受奥美卡替(n=185)或安慰剂(n=91),249例(90%)完成试验;2019年3月至2021年5月在北美和欧洲63个中心入组,末次患者访视于2021年11月29日。
- 主要终点:峰值摄氧量从基线至第20周的变化两组无显著差异(奥美卡替组均值-0.24 mL/kg/min vs 安慰剂组0.21 mL/kg/min;最小二乘均值差-0.45 mL/kg/min [95%CI,-1.02至0.13];P=0.13)。
- 中位基线峰值摄氧量:奥美卡替组14.2 mL/kg/min(IQR,11.6-17.4),安慰剂组15.0 mL/kg/min(IQR,12.0-17.2);中位左心室射血分数28%(IQR,21-33);中位年龄64岁(IQR,55-70岁);女性42例(15%)。
- 不良事件:头晕(奥美卡替4.9% vs 安慰剂5.5%)、乏力(4.9% vs 4.4%)、心力衰竭事件(4.9% vs 4.4%)、死亡(1.6% vs 1.1%)、卒中(0.5% vs 1.1%)、心肌梗死(0% vs 1.1%)。
证据类型、等级与局限
- 证据类型:3期双盲安慰剂对照随机临床试验(METEORIC-HF)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者结论认为,这些发现不支持使用奥美卡替治疗射血分数降低的心力衰竭以改善运动能力。
指南或共识出处
- METEORIC-HF随机临床试验,ClinicalTrials.gov注册号NCT03759392。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Exercise limitation is a cardinal manifestation of heart failure with reduced ejection fraction (HFrEF) but is not consistently improved by any of the current guideline-directed medical therapies.
OBJECTIVE: To determine whether omecamtiv mecarbil, a novel direct myosin activator that improves cardiac performance and reduces the risk for cardiovascular death or first HF event in HFrEF, can improve peak exercise capacity in patients with chronic HFrEF.
DESIGN, SETTING, AND PARTICIPANTS: Phase 3, double-blind, placebo-controlled randomized trial of patients with HFrEF (left ventricular ejection fraction ≤35%), New York Heart Association class II-III symptoms, N-terminal pro-B-type natriuretic peptide level of 200 pg/mL or greater, and baseline peak oxygen uptake (V̇o2) of 75% or less of predicted. Patients were randomized in a 2:1 ratio (omecamtiv mecarbil to placebo) between March 2019 and May 2021 at 63 sites in North America and Europe, with the last patient visit occurring on November 29, 2021.
INTERVENTIONS: Omecamtiv mecarbil (n = 185) or matching placebo (n = 91), given orally twice daily at a dose of 25 mg, 37.5 mg, or 50 mg based on target plasma levels, for 20 weeks.
MAIN OUTCOMES AND MEASURES: The primary end point was a change in exercise capacity (peak V̇o2) from baseline to week 20. Secondary end points included total workload, ventilatory efficiency, and daily physical activity as determined by accelerometry.
RESULTS: Among 276 patients who were randomized (median age, 64 years; IQR, 55-70 years; 42 women [15%]), 249 (90%) completed the trial. The median left ventricular ejection fraction was 28% (IQR, 21-33) and the median baseline peak V̇o2 was 14.2 mL/kg/min (IQR, 11.6-17.4) in the omecamtiv mecarbil group and 15.0 mL/kg/min (IQR, 12.0-17.2) in the placebo group. Mean change in peak V̇o2 did not differ significantly between the omecamtiv mecarbil and placebo groups (mean, -0.24 mL/kg/min vs 0.21 mL/kg/min; least square mean difference, -0.45 mL/kg/min [95% CI, -1.02 to 0.13]; P = .13). Adverse events included dizziness (omecamtiv mecarbil: 4.9%, placebo: 5.5%), fatigue (omecamtiv mecarbil: 4.9%, placebo: 4.4%), heart failure events (omecamtiv mecarbil: 4.9%, placebo: 4.4%), death (omecamtiv mecarbil: 1.6%, placebo: 1.1%), stroke (omecamtiv mecarbil: 0.5%, placebo: 1.1%), and myocardial infarction (omecamtiv mecarbil: 0%, placebo: 1.1%).
CONCLUSIONS AND RELEVANCE: In patients with chronic HFrEF, omecamtiv mecarbil did not significantly improve exercise capacity over 20 weeks compared with placebo. These findings do not support the use of omecamtiv mecarbil for treatment of HFrEF for improvement of exercise capacity.
TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03759392.
参考来源
- Lewis GD, Voors AA, Cohen-Solal A, et al. Effect of Omecamtiv Mecarbil on Exercise Capacity in Chronic Heart Failure With Reduced Ejection Fraction: The METEORIC-HF Randomized Clinical Trial. JAMA. 2022. PMID: 35852527. doi:10.1001/jama.2022.11016
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。